What does Axil Bio do?

Axil Bio is a commercial agency in Wevelgem. Private Limited, started on 27 June 2018, 1 establishment.

What is the address of Axil Bio?

The registered office of Axil Bio is located at Vlamingstraat 4, 8560 Wevelgem.

Is Axil Bio still active?

Yes. According to the CBE (29 October 2026) Axil Bio is active, legal situation “Normale toestand”, started on 27 June 2018.

Is Axil Bio registered on Peppol?

Yes, Axil Bio is registered on the Peppol network with ID 0208:0698854118.

What is the enterprise number of Axil Bio?

The enterprise number of Axil Bio is BE0698854118.

When was Axil Bio founded?

Axil Bio was founded on 27 June 2018.

Who are the directors of Axil Bio?

According to the 2025 annual accounts, the directors of Axil Bio are: Helys Group BV.

Is Axil Bio a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 June 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Axil Bio make in 2025?

Axil Bio posted a profit after taxes of € 7,603 in financial year 2025.

What is the revenue of Axil Bio?

As a small company, Axil Bio is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 21,348.

Axil Bio (Private Limited) - Wevelgem - BE0698854118

Dossier Axil Bio, printed on 29 October 2026 from databakkes.be/en/0698854118/axil-bio. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

22 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

Axil Bio from Wevelgem, company number BE0698854118, closed financial year 2025 with a result of € 7,603 after tax. For that financial year Axil Bio recorded a gross margin of € 21,348 and equity of € 139,580. Compared with financial year 2024, the result moved from € 7,747 to € 7,603. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.

What it is worth Growing

€ 139,580

▲ 6% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 7,603

▼ 2% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 35,415

▼ 52% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 109,080.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,806

▼ 55% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,426

▲ 43% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 201,450 Gross margin 2022: € 201,450 First fiscal year in the series	€ -14,205 Gross margin 2023: € -14,205 ▼ € 215,654 vs 2022 (€ 201,450) Unfavourable step	€ 28,058 Gross margin 2024: € 28,058 ▲ € 42,262 vs 2023 (€ -14,205) Favourable step	€ 21,348 Gross margin 2025: € 21,348 ▼ 24% vs 2024 (€ 28,058) Unfavourable step	▼ 24%
Profit after taxes	€ 133,724 Profit after taxes 2022: € 133,724 First fiscal year in the series	€ -68,195 Profit after taxes 2023: € -68,195 ▼ € 201,919 vs 2022 (€ 133,724) Unfavourable step	€ 7,747 Profit after taxes 2024: € 7,747 ▲ € 75,942 vs 2023 (€ -68,195) Favourable step	€ 7,603 Profit after taxes 2025: € 7,603 ▼ 2% vs 2024 (€ 7,747) Unfavourable step	▼ 2%
Equity	€ 252,425 Equity 2022: € 252,425 First fiscal year in the series	€ 184,230 Equity 2023: € 184,230 ▼ 27% vs 2022 (€ 252,425) Unfavourable step	€ 131,977 Equity 2024: € 131,977 ▼ 28% vs 2023 (€ 184,230) Unfavourable step	€ 139,580 Equity 2025: € 139,580 ▲ 6% vs 2024 (€ 131,977) Favourable step	▲ 6%
Total debts	€ 110,334 Total debts 2022: € 110,334 First fiscal year in the series	€ 45,674 Total debts 2023: € 45,674 ▼ 59% vs 2022 (€ 110,334) Favourable step	€ 101,298 Total debts 2024: € 101,298 ▲ 122% vs 2023 (€ 45,674) Unfavourable step	€ 37,302 Total debts 2025: € 37,302 ▼ 63% vs 2024 (€ 101,298) Favourable step	▼ 63%
Cash	€ 133,147 Cash 2022: € 133,147 First fiscal year in the series	€ 70,995 Cash 2023: € 70,995 ▼ 47% vs 2022 (€ 133,147) Unfavourable step	€ 74,188 Cash 2024: € 74,188 ▲ 4% vs 2023 (€ 70,995) Favourable step	€ 35,415 Cash 2025: € 35,415 ▼ 52% vs 2024 (€ 74,188) Unfavourable step	▼ 52%
Retained profit	€ 221,925 Retained profit 2022: € 221,925 First fiscal year in the series	€ 153,730 Retained profit 2023: € 153,730 ▼ 31% vs 2022 (€ 221,925) Unfavourable step	€ 101,477 Retained profit 2024: € 101,477 ▼ 34% vs 2023 (€ 153,730) Unfavourable step	€ 109,080 Retained profit 2025: € 109,080 ▲ 7% vs 2024 (€ 101,477) Favourable step	▲ 7%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 60,000 Dividend 2024: € 60,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 60,000) Unchanged	▼ 100%
Bank debt	€ 55,615 Bank debt 2022: € 55,615 First fiscal year in the series	€ 30,000 Bank debt 2023: € 30,000 ▼ 46% vs 2022 (€ 55,615) Favourable step	€ 30,000 Bank debt 2024: € 30,000 Unchanged (€ 30,000) Unchanged	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 30,000) Favourable step	▼ 100%
Balance sheet total	€ 362,759 Balance sheet total 2022: € 362,759 First fiscal year in the series	€ 229,904 Balance sheet total 2023: € 229,904 ▼ 37% vs 2022 (€ 362,759) Unchanged	€ 233,275 Balance sheet total 2024: € 233,275 ▲ 1% vs 2023 (€ 229,904) Unchanged	€ 176,882 Balance sheet total 2025: € 176,882 ▼ 24% vs 2024 (€ 233,275) Unchanged	▼ 24%

Key figures of Axil Bio, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Axil Bio?

What happened at Axil Bio in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 1, 2026 New annual accounts for financial year 2025: profit of € 7,603 (▼ 2% vs 2024). Source: NBB ↗
2024 Helys Group BV became a director. NBB
Jun 27, 2018 New establishment in Wevelgem. KBO
Jun 27, 2018 Start of the company according to the CBE. KBO

In short

From € 133,724 profit in 2022 to € 7,603 profit in 2025.

Paid € 45,201 in corporate taxes since 2022.

Best year ever: 2022, with € 133,724 profit.

Paid out € 60,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Helys Group 100%

The stake of Helys Group comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Axil Bio

Behind Axil Bio is Helys Group BV. The shares are held by Helys Group (100%).

Directors

According to the 2025 annual accounts

Helys Group BV

Director · represented by PHILIPPE LOIR

Also active at: SOPACHEM

since 2024

Shareholders

Helys Group

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Vlamingstraat 4

8560 Wevelgem

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 22 companies are registered at this address.

All companies at this address →

Takeoff Business Hub

€ 357,632 gross margin · 2025

INTERTRADE

JACOTI

€ -1.1 million gross margin · 2025

EXCEPT

€ -6,464 gross margin · 2026

NEXUS ASTRAIA BV

€ 906,898 gross margin · 2025

+17 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0698.854.118
VAT number: BE 0698.854.118
Registered office: Vlamingstraat 4, 8560 Wevelgem
Names & denominations: Axil Bio · PINKY SWEAR
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 27 June 2018
Peppol: Active · Active since 20 Nov 2020
Activities · NACE: Handelsbemiddeling in de groothandel in andere specifieke goederen

View on CBE Public ↗ Annual accounts (NBB) ↗